We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Faded Promises: The Challenge of Deadopting Low-Value Care.
- Authors
Roman, Benjamin R.; Asch, David A.
- Abstract
In this article, the author reflects on the withdrawal of the approval of bevacizumab drug for metastatic breast cancer by the U.S. Food and Drug Administration (FDA) in the U.S. Topics discussed include approval of low-value medical care and services, reduced use of low-value health care services, and psychological challenge of withdrawal by influencing drugs from the market.
- Subjects
UNITED States; DRUG approval laws; BEVACIZUMAB; UNITED States. Food &; Drug Administration; BREAST cancer treatment; MEDICAL care; GOVERNMENT policy
- Publication
Annals of Internal Medicine, 2014, Vol 161, Issue 2, p149
- ISSN
0003-4819
- Publication type
Opinion
- DOI
10.7326/M14-0212